Puma Biotechnology (NASDAQ: PBYI) is one of 180 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Puma Biotechnology to similar businesses based on the strength of its profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
Institutional and Insider Ownership
96.0% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 21.1% of Puma Biotechnology shares are owned by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Puma Biotechnology and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Puma Biotechnology Competitors||-4,721.93%||-493.38%||-42.01%|
Risk & Volatility
Puma Biotechnology has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Puma Biotechnology’s rivals have a beta of 1.53, meaning that their average stock price is 53% more volatile than the S&P 500.
This is a breakdown of recent ratings for Puma Biotechnology and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Puma Biotechnology Competitors||544||2435||6655||131||2.65|
Puma Biotechnology currently has a consensus price target of $130.67, suggesting a potential upside of 31.79%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 16.74%. Given Puma Biotechnology’s stronger consensus rating and higher probable upside, equities analysts plainly believe Puma Biotechnology is more favorable than its rivals.
Valuation & Earnings
This table compares Puma Biotechnology and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Puma Biotechnology||N/A||-$276.01 million||-12.11|
|Puma Biotechnology Competitors||$217.36 million||-$39.57 million||-38.16|
Puma Biotechnology’s rivals have higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Puma Biotechnology beats its rivals on 8 of the 13 factors compared.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.